CD274 and small cell lung carcinoma: The SCLC patients’ percentage who had prior immunotherapy (e.g., PD-1/PD-L1 inhibitors) in our study (dose-expansion stage) was much higher than the basket trial result (SCLC cohort): 63.6% (14/22) vs. 7.6% (8/105), which could be attributed to the different timings of both the studies.